COMP <GO>
KNSA vs IONS // FREE CASH FLOW YIELD
Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) VS. Ionis Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: KNSA 10
— IONS 2
▲ FREE CASH FLOW YIELD LEADER: KNSA
LAST: $90.80 (-1.56%) • MKT CAP: $7.25B
fcf-yield
1.78%
LAST: $41.24 (-5.24%) • MKT CAP: $7.23B
fcf-yield
-4.34%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. IONS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | IONS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 96.00% | -7.50 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -20.90% | +30.80 | KNSA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.78% | -4.34% | +6.12 | KNSA | /fcf-yield <GO> |
| Operating Margin | 11.40% | -40.40% | +51.80 | KNSA | /operating-margins <GO> |
| Net Profit Margin | 8.70% | -40.40% | +49.10 | KNSA | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 33.80% | +26.30 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.45 | 1.08 | +23.37 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.2 | 43.6 | +15.60 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.09 | +0.02 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 22.0x | +87.10 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.25B | $7.23B | $15.1M | KNSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | IONS REV | KNSA GROSS % | IONS GROSS % | KNSA FCF | IONS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $943.7M | 88.5% | 98.3% | $136.4M | -$320.0M |
| FY 2024 | $423.2M | $705.1M | 85.6% | 98.4% | $25.4M | -$546.2M |
| FY 2023 | $270.3M | $787.6M | — | — | $1.1M | -$343.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
IONS // BETA 1.09